4.5 Article

Remote electrical neuromodulation for migraine prevention: A double-blind, randomized, placebo-controlled clinical trial

Journal

HEADACHE
Volume 63, Issue 3, Pages 377-389

Publisher

WILEY
DOI: 10.1111/head.14469

Keywords

headache; migraine; neuromodulation; non-pharmacological; prevention; prophylaxis

Ask authors/readers for more resources

A study found that remote electrical neuromodulation (REN) is effective in preventing migraines when used every other day, with significant reductions in the number of migraine days and severity of headaches.
Objective: To assess the clinical efficacy of remote electrical neuromodulation (REN), used every other day, for the prevention of migraine.Background: Preventive treatment is key to managing migraine, but it is often underutilized. REN, a non-pharmacological acute treatment for migraine, was evaluated as a method of migraine prevention in patients with episodic and chronic migraine. Methods: We conducted a prospective, randomized, double-blind, placebo-controlled, multi-center trial, with 1:1 ratio. The study consisted of a 4- week baseline observation phase, and an 8- week double -blind intervention phase in which participants used either REN or a placebo stimulation every other day. Throughout the study, participants reported their symptoms daily, via an electronic diary.Results: Two hundred forty- eight participants were randomized (128 active, 120 pla-cebo), of which 179 qualified for the modified intention- to- treat (mITT) analysis (95 active; 84 placebo). REN was superior to placebo in the primary endpoint, change in mean number of migraine days per month from baseline, with mean reduction of 4.0 +/- SD of 4.0 days (1.3 +/- 4.0 in placebo, therapeutic gain = 2.7 [confidence interval -3.9 to -1.5], p < 0.001). The significance was maintained when analyzing the episodic (-3.2 +/- 3.4 vs. -1.0 +/- 3.6, p = 0.003) and chronic (-4.7 +/- 4.4 vs. -1.6 +/- 4.4, p = 0.001) migraine subgroups separately. REN was also superior to placebo in reduction of mod-erate/severe headache days (3.8 +/- 3.9 vs. 2.2 +/- 3.6, p = 0.005), reduction of head-ache days of all severities (4.5 +/- 4.1 vs. 1.8 +/- 4.6, p < 0.001), percentage of patients achieving 50% reduction in moderate/severe headache days (51.6% [49/95] vs. 35.7% [30/84], p = 0.033), and reduction in days of acute medication intake (3.5 +/- 4.1 vs. 1.4 +/- 4.3, p = 0.001). Similar results were obtained in the ITT analysis. No serious device-related adverse events were reported in any group.Conclusion: Applied every other day, REN is effective and safe for the prevention of migraine.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available